Stallone et al. analyzed the potential of PTX-3 to discriminate tissue inflammation and benign prostatic hyperplasia from prostate cancer by evaluating both serum concentrations and tissular expression [36]. This evidence concerns the gene PTX3 and benign prostatic hyperplasia.